



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

21 Sep 2020 (#42)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

**Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)**

## Important Notices

- **[NOT-OD-20-174](#): Reminder: NIH Policy on Use of Hypertext in NIH Grant Applications.** This notice serves to remind grant applicants about existing guidance that **restricts use of hypertext** (e.g., hyperlinks and URLs) in NIH applications. Increasing use of unallowable hypertext in NIH grant applications raises multiple concerns and applications that do not follow the instructions, and include unallowable hyperlinks, will be withdrawn from review and funding consideration.
- **[NOT-HL-20-814](#): Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI).** The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of National Heart, Lung, and Blood Institute (NHLBI) in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).

## Upcoming Deadlines

- **[Harnessing Data Science for Health Discovery and Innovation in Africa \(DS-I Africa\)](#):**  
Research Training Program due date: 24 November 2020  
Ethical, Legal, and Social Implications Research due date: 1 December 2020  
Open Data Science Platform and Coordinating Center due date: 3 December 2020  
Research Hubs non-AIDS application due date: 8 December 2020  
Research Hubs AIDS application due date: 8 February 2021
- **[Mobile Health: Technology and Outcomes in LMICs](#)** AIDS deadline 3 December 2020
- **[Emerging Global Leader Award](#)** 4 November 2020
- **[Global Brain Disorders Research](#)** 6 November 2020
- **[Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in LMICs](#)** 12 November 2020
- **[Chronic, Noncommunicable Diseases and Disorders Research Training \(NCD-Lifespan\)](#)** D43 13 November 2020
- **[Ecology and Evolution of Infectious Diseases Initiative \(EEID\)](#)** 18 November 2020
- **[Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries](#)** D43 24 June 2021

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- **[PA-20-185](#)** NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- **[PA-20-184](#)** Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Funding Opportunities

### 1. Cancer Intervention and Surveillance Modeling Network (CISNET) Incubator Program for New Cancer Sites (U01 Clinical Trial Not Allowed)

**Letter of Intent: 30 days prior to the application due date**

**Hyperlink:** [RFA-CA-20-043](#)

**Type:** U01

**Application Due Date:** January 20, 2021. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites multiple-PD/PI applications for collaborative research projects each with two to three independent modeling groups that will comprise a new "incubator" program within the [Cancer Intervention and Surveillance Modeling Network](#) (CISNET). The overarching goal of this FOA is to expand comparative simulation modeling approaches developed by CISNET to new cancer organ sites beyond the sites which have been previously funded (breast, colorectal, prostate, lung, esophageal, and cervical) under CISNET. This "incubator" FOA is open to any cancer organ site beyond these sites. Specifically, this program aims to translate CISNET's framework of success to cancer sites that are not already part of the CISNET and for which there has been nascent/limited population modeling and little to no comparative modeling. For this FOA, "incubate" refers to accelerating the development and application of CISNET-type models for new cancer sites. Accelerating the development of comparative simulation modeling approaches for new cancer organ sites beyond those already funded is expected to generate sophisticated, evidence-based decision tools that could inform decisions on the most efficient utilization of existing and emerging technologies and strategies for the control of proposed cancers. While open to all qualified investigators, to encourage broad participation from population modelers in cancer control, this FOA will allow no more than one Principal Investigator who is funded under the CISNET FOA [RFA-CA-19-054](#) to also be a Principal Investigator on each Incubator application.

**Budget:** The NCI intends to commit \$4 million (total cost) in FY 2021 to fund up to four awards. The budget request (direct cost) for the entire application per year should not exceed \$490,000 and \$670,000 for two and three modeling groups, respectively. A project period of up to five years may be proposed.

### 2. BRAIN Initiative: Pilot resources for brain cell type-specific access and manipulation across vertebrate species (U01 Clinical Trial Not Allowed)

**Letter of Intent: 30 days prior to the application due date**

**Hyperlink:** [RFA-MH-20-556](#)

**Type:** U01

**Application Due Date:** February 11, 2021; October 19, 2021. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support the development of technologies, production efforts, and dissemination resources for a cell type-specific armamentarium to study brain function across species. The goal is to promote evaluation of molecular or genetic technologies and creation of pilot production and distribution resources for cell type-specific access and manipulation reagents for several vertebrate species, including in human ex vivo tissues or cells. Demonstration projects are sought that would develop reagents that: (1) enable access to molecularly defined neural cell types in a complex brain region or significant brain network of a vertebrate; (2) are easily produced, disseminated, utilized, and stored; and (3) are catalogued for users in a brain atlas. In addition to the above required features, reagents are also sought that exhibit the following qualities: (4) are applicable to both genetically tractable and less tractable vertebrate organisms; (5) exhibit high specificity and efficiency of targeting; (6) show low toxic or perturbative effects; (7) provide flexibility to deliver various reporter, sensor, and effector payloads and are compatible with other methods of access to brain cell types; and (8) are potentially usable in human ex vivo brain tissue or cells. The pilot projects should be scalable in the future. The long-term goal of a potentially scaled-up effort is to achieve near comprehensive, molecular access for monitoring and manipulation reagents in each defined cell type of vertebrate brains relevant to neuroscience research.

**Budget:** Issuing IC and partner components intend to commit an estimated total of \$10,000,000 per year to fund 4 to 6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 3 years.

### 3. HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

**Letter of Intent: 30 days prior to the application due date**

**Hyperlink:** [RFA-NS-21-010](#)

**Type:** UG3/UH3

**Application Due Date:** November 18, 2020, March 24, 2021, July 14, 2021, October 15, 2021, February 15, 2022, June 15, 2022 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) <https://heal.nih.gov/research/clinical-research/eppic-net> or other Phase II clinical studies. Applicants must have a promising biologic or small molecule hit/lead, robust biological rationale for the intended approach, and identified

assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, development of a pharmacodynamic/target engagement biomarker, assembly and filing of an Investigational New Drug (IND) application and Phase I clinical testing. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.

**Budget:** NIH intends to fund an estimated 5 awards for fiscal year 2021. Future awards will depend on annual appropriations. Application budgets must reflect the actual needs of the proposed project but should not include the costs of NIH contract resources requested. The total duration may not exceed 5 years.

**Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University**  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

**Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University**  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizel*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105